Paperpal Prime Logo

Breast : Impact Factor & More

eISSN: 1532-3080pISSN: 0960-9776
JournalOpen Access

Aims and Scope of Breast

The Breast is a peer-reviewed medical journal published by Elsevier covering research on breast cancer.

Key Metrics

CiteScore
6.7
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
SJR
Q2Surgery
SNIP
1.41
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Breast

Breast Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher CHURCHILL LIVINGSTONE
Language English
Frequency Bi-monthly
Article Processing ChargesUSD 2630
Publication Time5
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorAustralasian Society for Breast Disease
FrequencyBi-monthly
Publication Start Year1992
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 5
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Breast ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Breast

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Emotional distress, guilt and impact on reproductive decision-making in women with BRCA1/2 mutations.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Prognostic scoring based on ER, PgR and HER2-low from the CYCLHER study: strengths and unaddressed challenges for global clinical application.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Factors associated with local breast cancer recurrence after mastectomy in the Netherlands: a retrospective nationwide cohort study.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Emotional distress, guilt and impact on reproductive decision-making in women with BRCA1/2 mutations.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Prognostic scoring based on ER, PgR and HER2-low from the CYCLHER study: strengths and unaddressed challenges for global clinical application.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)
Factors associated with local breast cancer recurrence after mastectomy in the Netherlands: a retrospective nationwide cohort study.
  • 1 Aug 2026
  • Breast (Edinburgh, Scotland)

FAQs on Breast